

Growth Hormone Prior Authorization of Benefits Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 844-512-9004 or Provider Help Desk 800-454-3730

| 1. Patient information | 2. Physician information |
|------------------------|--------------------------|
| Patient name: | Prescribing physician: |
| Patient ID #: | Physician address: |
| Patient DOB: | Physician phone #: |
| Date of Rx: | Physician fax #: |
| Patient phone #: | Physician specialty: |
| Patient email address: | Physician DEA: |
| | Physician NPI #: |
| | Physician email address: |
| | |
| | |

| 3. Medication | 4. Strength | 5. Directions | 6. Quantity per 30 days |
|---------------|-------------|---------------|-------------------------|
| | | | Specify: |
| 7.Diagnosis: | | | |
| | | | |

8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Prior authorization (PA) is required for therapy with growth hormones. Requests will only be considered for FDA-approved dosing. Payment for non-preferred growth hormones will be authorized only for cases in which there is documentation of previous trial and therapy failure with a preferred agent. The following FDA approved indications for Growth Hormone therapy are considered not medically necessary and requests will be denied; Idiopathic Short Stature (ISS) and Small for Gestational Age (SGA). If the criteria for coverage are met, initial requests will be given for 12-months, unless otherwise stated in criteria. Additional prior authorizations will be considered upon documentation of clinical response to therapy and patient continues to meet the criteria for the submitted diagnosis.

| Preferred | Non- Preferred | |
|--|----------------------------|---|
| 🗆 Norditropin | 🗆 Genotropin | 🗆 Saizen |
| 🗆 Nutropin AQ NuSpin | ☐ Humatrope | 🗆 Tev-Tropin |
| | □ Omnitrope | |
| | · | |
| Number of vials per month: | Estimate lengt | h of therapy: |
| Previous Growth Hormone Therapy (incl | ude drug name(s), streng | gth, and exact date ranges): |
| | | |
| | | |
| | | |
| Reason for use of Non-Preferred drug red | uiring prior approval: | |
| | 19 h | |
| | | |
| | | |
| | | |
| Children with Growth Hormone Defic | • | |
| 1. Standard deviation of 2.0 or more belo | - | |
| 2. No expanding intracranial lesion or tun | • • • | d |
| Growth rate below five centimeters pe Failure of any two stimuli tests to raise | • | no lovel above ten nanograms per |
| milliliter; and | the seruin growth hornit | one level above ten hanograms per |
| | bone age 14 to 15 years o | or less in females and 15 to 16 years or less |
| in males is required; and | | |
| 6. Epiphyses open | | |
| Bone Age: Date of Bone | Age Test: | Epiphyses open? 🗆 Yes 🔲 No |
| Height: Weight: | | |
| Weight percentile: | | |
| Is standard deviation 2.0 or more below | mean height for chronolog | gical age? 🗆 Yes 🖾 No |
| MRI diagnosis: | | Date: |
| Growth rate per year: | | |
| Pertinent Medical History including grow | th pattern, diagnostic tes | t, treatment plan, and response so far: |
| | | |
| | | |
| Please provide two stimuli tests and resu | lts: | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Pediatric Chronic Kidney Disease 1. Is prescribed by or in consultation with a nephrologist; and 2. Standard deviation of 2.0 or more below mean height for chronologi 3. No expanding intracranial lesion or tumor diagnosed by MRI; and 4. Growth rate below five centimeters per year; and 5. A bone age 14 to 15 years or less in females and 15 to 16 years or less 6. Epiphyses open Bone Age: Date of Bone Age Test: | s in males is required; and | | |
|--|------------------------------|--|--|
| Height: Weight: Height percentile at time of dia Weight percentile: | | | |
| Is standard deviation 2.0 or more below mean height for chronological MRI diagnosis: Growth rate per year: | Date: | | |
| Is prescriber a nephrologist? Yes No If no, note consultation with r Consultation date: Physician name and phone: | nephrologist: | | |
| Turner's Syndrome Chromosomal abnormality showing Turner's syndrome; and | | | |
| 2. Prescribed by or in consultation with an endocrinologist; and | | | |
| 3. Standard deviation of 2.0 or more below mean height for chronologi | cal age; and | | |
| 4. No expanding intracranial lesion or tumor diagnosed by MRI; and | | | |
| 5. Growth rate below five centimeters per year; and | | | |
| 6. A bone age 14 to 15 years or less in females and 15 to 16 years or les | s in males is required; and | | |
| 7. Epiphyses open. | | | |
| Chromosomal abnormality showing Turner's syndrome? \Box Yes (attach | results) 🗆 No | | |
| Bone Age: Date of Bone Age Test: | _ Epiphyses open? 🗆 Yes 🗆 No | | |
| Height: Weight: Height percentile at time of dia | agnosis: | | |
| Weight percentile: | | | |
| Is standard deviation 2.0 or more below mean height for chronological | age? 🗆 Yes 🗆 No | | |
| MRI diagnosis: | Date: | | |
| Growth rate per year: | | | |
| Is prescriber an endocrinologist? 🗆 Yes 🗆 No | | | |
| If no, note consultation with endocrinologist: | | | |
| Consultation date: | | | |
| Physician name and phone: | | | |
| Prader Willi Syndrome Diagnosis is confirmed by appropriate genetic testing (attach results) | . and | | |
| 2. Prescribed by or in consultation with an endocrinologist; and | | | |
| 3. A bone age 14 to 15 years or less in females and 15 to 16 years or less in males is required; and | | | |
| 4. Epiphyses open | | | |
| Diagnosis confirmed by genetic testing? \Box Yes (attach results) \Box No | | | |
| | | | |

| Bone Age: Date of Bone Age Test: E Is prescriber an endocrinologist? 		Yes 	No If no, note consultation with endocrinologist: Consultation date: Physician name and phone: | |
|--|--|
| Noonan Syndrome Diagnosis is confirmed by appropriate genetic testing (attach results); Prescribed by or in consultation with an endocrinologist; and Standard deviation of 2.0 or more below mean height for chronologica A bone age 14 to 15 years or less in females and 15 to 16 years or less Epiphyses open Diagnosis confirmed by genetic testing? Yes (attach results) No | al age; and |
| Bone Age: Date of Bone Age Test: E Is prescriber an endocrinologist? | |
| Height: | diagnosis: |
| SHOX (Short Stature Homeobox) Diagnosis is confirmed by appropriate genetic testing (attach results); Prescribed by or in consultation with an endocrinologist; and A bone age 14 to 15 years or less in females and 15 to 16 years or less Epiphyses open. | |
| Diagnosis confirmed by genetic testing? Yes (attach results) No Bone Age: Date of Bone Age Test: E Is prescriber an endocrinologist? Yes No If no, note consultation with endocrinologist: Consultation date: Physician name and phone: | |
| Adults with Growth Hormone Deficiency Patients who were growth hormone deficient during childhood (childh deficiency; or Patients who have growth hormone deficiency (adult onset) as a result disease (e.g. panhypopituitarism, pituitary adenoma, trauma, cranial irra Failure of at least one growth hormone stimulation test as an adult with 5 mcg/L after stimulation. | nood onset) and who have continued t of pituitary or hypothalamic diation, pituitary surgery); and |

| □ Adult Onset: provide pituitary or hypothalamic disease diagnosis: |
|--|
| Please provide stimuli test, date and result: |
| Adults with AIDS Wasting/Cachexia Greater than 10% of baseline weight loss over 12 months that cannot be explained by a concurrent illness other than HIV infection; and Patient is currently being treated with antiviral agents; and Patient has documentation of a previous trial and therapy failure with an appetite stimulant (i.e. dronabinol or megestrol). |
| Has patient experienced > 10% weight loss over 12 months? □ Yes □ No Baseline weight and date: Current weight and date: |
| Does patient have concurrent illness other than HIV infection contributing to weight loss? Yes No Current antiviral treatment: Drug name, dosing & trial dates: |
| |
| Appetite stimulant trial: Drug name and dose: Trial dates: Failure reason: |
| Short Bowel Syndrome If the request is for Zorbtive [somatropin (rDNA origin) for injection] approval will be granted in patients receiving specialized nutritional support. Zorbtive therapy should be used in conjunction with optimal management of short bowel syndrome. PA will be considered for a maximum of four weeks. Provide nutritional support plan: |
| Renewals (in addition to above criteria) Clinical response to therapy: |
| |
| Reason for use of non-preferred drug requiring PA: |
| Attach lab results and other documentation as necessary. |
| 9. Physician signature |

Prescriber or authorized signature

Date

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient. Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Important note: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.